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Abstract The Center for Eukaryotic Structural Genomics
(CESG) is a ‘‘specialized’’ or ‘‘technology development’’
center supported by the Protein Structure Initiative (PSI).
CESG’s mission is to develop improved methods for the
high-throughput solution of structures from eukaryotic
proteins, with a very strong weighting toward human pro-
teins of biomedical relevance. During the ﬁrst three years
of PSI-2, CESG selected targets representing 601 proteins
from Homo sapiens, 33 from mouse, 10 from rat, 139 from
Galdieria sulphuraria, 35 from Arabidopsis thaliana,9 6
from Cyanidioschyzon merolae, 80 from Plasmodium fal-
ciparum, 24 from yeast, and about 25 from other
eukaryotes. Notably, 30% of all structures of human pro-
teins solved by the PSI Centers were determined at CESG.
Whereas eukaryotic proteins generally are considered to be
much more challenging targets than prokaryotic proteins,
the technology now in place at CESG yields success rates
that are comparable to those of the large production centers
that work primarily on prokaryotic proteins. We describe
here the technological innovations that underlie CESG’s
platforms for bioinformatics and laboratory information
management, target selection, protein production, and
structure determination by X-ray crystallography or NMR
spectroscopy.
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Abbreviations
CESG Center for Eukaryotic Structural Genomics
FTE Full time equivalent
HSQC Heteronuclear single quantum correlation
LIMS Laboratory information management system
OMIM Online Mendelian Inheritance in Man Database
PSI Protein Structure Initiative
RDBMS Relational database management system
WG Workgroup
Introduction
TheProteinStructureInitiative(PSI),whichisfundedbythe
National Institute for General Medical Sciences, supports a
network of four production centers, ten ‘‘specialized’’ or
technology development centers, two modeling centers, the
PSI Knowledgebase, and the PSI Materials Repository. As a
means of disseminating information about the program,
various centers were invited to submit accounts abstracted
from their 2007–2008 Annual Report to the PSI. This
account describes the Center for Eukaryotic Structural
Genomics (CESG). CESG focuses on the development of
technology for improving success rates and lowering costs
of structure determinations of human proteins related to
disease or cell differentiation and proteins from families
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DOI 10.1007/s10969-008-9057-4represented onlyineukaryotes.Weseek toexpand the range
of targets amenable to structure determination to membrane
proteins and proteins with N- or C-terminal membrane
anchors.
In choosing new targets, CESG takes three factors into
account: (1) the likelihood that its structure will improve
our understanding of sequence-structure relationships
(sequence of the target less than 30% identical to any in a
known structure), (2) the likelihood that a structure will
advance our understanding of a human disease, metabolic
pathway, or genetic disorder, and (3) the likelihood that the
target will be produced as a folded protein amenable to
structure determination. The highest ranked targets meet all
three of these criteria. CESG also invites the nomination of
targets by members of the scientiﬁc community. Those that
are approved must be acceptable under criterion (3) and be
favorable under one or both of criteria (1) and (2). In
addition, CESG gives preference to targets that may lead to
functional characterization of the system studied by the
outside collaborator.
CESG justiﬁes its exclusive focus on proteins from
humans and other eukaryotes as follows. Eukaryotes con-
tain a large number of sequence-structure targets (both full-
length proteins and domains) that are not represented in
prokaryotes. It is clear that the PSI will need to solve
structures of eukaryotic proteins in order to achieve its goal
of making ‘‘the three-dimensional atomic-level structures
of most proteins easily obtainable from knowledge of their
corresponding DNA sequences’’ [1]. Moreover, we foresee
no real substitutes for human proteins when it comes to
detailed investigations of diseases or studies aimed at
understanding complex processes, such as the differentia-
tion of human stem cells. Technological developments
made in the ﬁeld of eukaryotic protein production will have
wide applicability in many branches of biomedical
research, including antibody production, screening for
molecular interactions, and drug design. Human gene
products represent a grand challenge, because of their high
levels of gene splicing and the huge multiplicity of protein–
protein interactions known to occur. Improved methods for
preparing proteins from the human and related genomes
will open up structure-function investigations of these
targets. The presence of clones and protocols for preparing
these proteins in the PSI Materials Repository and
Knowledgebase will catalyze continued studies by the
biomedical community.
Eukaryotic proteins (particularly those from humans and
higher vertebrates) are difﬁcult targets for structural
genomics because of a number of factors. (1) The gene
models for eukaryotic proteins are poorly developed. (2)
Eukaryotic proteins contain a large number of introns and
are subject to alternative splicing patterns. (3) Eukaryotic
proteins frequently require chaperones for proper folding.
(4) Eukaryotic proteins contain considerably more regions
of intrinsic disorder, and a large fraction of them (*60%)
are fully natively disordered. (5) Because of difﬁculties in
producing and solubilizing them, few structures of
recombinant eukaryotic membrane proteins have been
determined. CESG focuses on developing technology to
overcome these difﬁculties. The approaches CESG has
been using toward technology development and the cen-
ter’s major accomplishments are summarized in Table 1.
CESG endeavors to make its technology available to the
scientiﬁc community. Efforts along these lines are sum-
marized in Table 2.
Organization of CESG
The majority of CESG’s co-investigators and employees
are located in the Biochemistry Department at the
University of Wisconsin-Madison. This concentration of
personnel has facilitated communication and resource
sharing, although in the past CESG placed strains on the
space and administrative infrastructure of the Department.
This year the majority of CESG staff was relocated to
newly remodeled laboratory space, and a new on-line
purchase ordering system was instituted to streamline
administrative processes. The only CESG consortium
partner is at the Medical College of Wisconsin (Milwau-
kee, WI); members of this group participate in CESG
meetings by video conferencing and visit Madison to
attend important meetings.
The CESG Executive Committee (the PI, co-PIs,
Bioinformatics/Crystallography Team Leader, and Project
Manager) coordinates the activities of the teams, provides
scientiﬁc direction, and sets long-term goals and strategies
of the project. This group meets weekly in Madison to
discuss agenda items, share news of recent conferences,
review outside requests, authorize the creation of work
groups, and surface any new concerns. Brian Volkman
attends from Milwaukee via videoconferencing. Directions
and initiatives from this committee are communicated to
the functional teams by the investigator at the team meet-
ings. Overall project progress and goals are shared at All-
Hands meetings which are held on a quarterly basis.
CESG is organized into eight functional teams, each
focused on fundamental aspects of the project. A PI or co-
Investigator is responsible for the overall operation of each
team; however, within each team, a PhD level scientist or
an experienced administrator (Team Leader) is responsible
for the day-to-day operation of the team and assists with
long-range planning. CESG tracks expenses by functional
teams: administration, cloning, small-scale expression
testing, large-scale E. coli production and puriﬁcation,
quality assurance, cell-free protein production, X-ray
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123crystallography, and NMR spectroscopy. Multiple sections
may be in one team (cloning, small-scale expression test-
ing, large-scale protein production, and cell-free sections
make up the Protein Production Research Team). This has
enabled the center to quantify supplies and labor costs for
activities associated with each section.
Progress in the development of new methods,
technology, approaches, and ideas for protein
production and structure determination
Platform for technology assessment
CESG has developed a multi-threaded platform (Fig. 1)
that covers all steps from target selection to structure
determination and data deposition. The platform supports
single-step cloning leading to multiple vector possibilities,
two complementary methods for producing protein (E. coli
cell-based and wheat germ cell-free), and two comple-
mentary methods for structure determination (X-ray
crystallography and NMR spectroscopy). CESG uses this
platform as a test-bed to evaluate the performance of new
technology as it is applied to challenging targets: soluble
proteins, membrane proteins, and proteins containing
membrane anchors or signal sequences from the genomes
of humans and higher vertebrates. The platform is inter-
faced to the Sesame laboratory information management
system (LIMS), which collects and organizes information
about targets and what is done with them (Table 4).
Throughout PSI-1 (2001–2005) and PSI-2 (2005–), CESG
has developed the capability of capturing of ﬁne-grained
Table 1 Technology developed at the Center for Eukaryotic Structural Genomics
Laboratory management and bioinformatics
Sesame LIMS [2]
Target tracking [3]
Impact of disorder on success of determining structures [4]
Impact of low-complexity sequence on producing proteins and determining structures [5]
Efﬁcient target scoring protocol (JCSG has adopted a similar protocol)
CESG is developing the best database of information on natively disordered eukaryotic proteins (from NMR screening) [unpublished]
Cloning, plasmid development, strain, and media development
FlexiVector cloning [6]
Vectors developed [6–10]
Autoinduction medium reﬁnement [8]
Autoinduction medium for Se-Met labeling [11]
Autoinduction medium for
15N and
13C labeling [9]
Application of the technology to the efﬁcient production of TEV protease [12]
Technology for expression and solubility screening and protein production
Control protein workgroups developed to test and verify protocols [to be published]
High-throughput cell-free screening on GenDecoder
TM 1000 at * 2 lg scale [13–16]
Maxwell-16 for cell-based screening and puriﬁcation at *1 mg scale [10]
and Protemist
TM DT-II for cell-free screening and puriﬁcation at *1 mg scale [to be published]
Comparisons of cell-free and cell-based protein production: original comparison [17]; new comparisons underway
AKTA-based semi-automated afﬁnity and gel ﬁltration puriﬁcation at 1–100 mg scale [18]
Technology for X-ray crystallography
High-throughput crystal screening technology, including CrystalFarm Pro [to be published]
Ensemble reﬁnements of crystal structures [19]
Automatic Crystallographic Map Interpreter (ACMI) [20]
Technology for NMR spectroscopy
HIFI-NMR fast 3D triple-resonance NMR data collection [21]
HIFI-C fast collection of coupling data for structural constraints [22]
PISTACHIO (automated assignments) [23]
LACS (automated validation) [24]
Improved analysis of NMR chemical shifts [25, 26]
PECAN (automated secondary structure determination) [27]
PINE (automated backbone and side chain assignments, secondary structure and validation) [28]
Stereo array isotope labeling (SAIL) approach for NMR structures of larger proteins [29]
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123information about individual pipeline steps into a single
relational database with its Sesame LIMS. This has
generated a huge database of information about the per-
formance of eukaryotic ORFs through the various steps
of our structural proteomics pipelines. The center uses
this information to identify the most critical steps for
improvement and to evaluate strategies for improving their
efﬁciency.
As a technology development center in PSI-2, CESG’s
approach has been to leverage its evolving protocols and
strengths in protein production by cell-based and cell-free
methods and structure determination by X-ray crystallo-
graphic and NMR spectroscopic methods to increase the
success rates and lower the costs of determining structures
of eukaryotic proteins, particularly human proteins and
proteins from higher vertebrates. CESG is unique as a PSI
specialized center in its ability to test new technologies at
all stages of the structure determination process, including
improved bioinformatics hypotheses for target selection,
experimental testing of the hypotheses, extensive capture
of experimental results into the Sesame LIMS system, and
automated deposition of experimental results in the PSI
Knowledge Base and PDB using specialized bioinformatics
software. One of the lessons CESG learned from its par-
ticipation in PSI-1 is that cell-based (E. coli)[ 8, 11] and
cell-free (wheat germ extract) [13–16] protein production
platforms offer complementary coverage in that targets that
fail with one approach may succeed with the other [17].
Similarly, X-ray crystallography and NMR were found to
offer complementary approaches to structure determina-
tion. Another lesson from PSI-1 was the importance of
developing fast and inexpensive screens for determining
the expression and solubility properties of targets that
accurately predict success in subsequent scale-up [10, 13].
Much of the research in PSI-2 has focused on perfecting a
robust platform that enables CESG to clone once and to
carry out inexpensive small-scale trials to determine pro-
tein production, tag cleavage (if relevant), and solubility in
both the cell-free and cell-based modalities.
CESG has continued to automate its X-ray crystallo-
graphic and NMR spectroscopic pipelines. With installa-
tion of a Mosquito system, CESG now can use smaller
quantities of protein for crystallization trials. CESG has
implemented small-scale hanging drop screening using the
Mosquito for identifying suitable solution conditions for
NMR spectroscopy and now uses 3 mm NMR sample
tubes to reduce protein sample requirements for
1H–
15N
HSQC screening.
The robustness of CESG’s platform is evident from
statistics for PSI efforts with eukaryotic proteins obtained
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Fig. 1 CESG’s structure determination platform interfaced with the
Sesame laboratory information management system
Table 2 Outreach activities (in PSI-2) at the Center for Eukaryotic Structural Genomics
Outside target requests: 293 submitted, 242 approved, 7 structures determined, 33 in progress
Material Transfer Agreements: 32 initiated
Collaborations on functional studies
Collaborative publications
Cell-free workshops
NMR workshops
OMIM human proteins (See Table 3 for success rates with all eukaryotic targets)
Sesame developed at CESG is the only LIMS to be used by multiple PSI centers: used by Structural Genomics of Pathogenic Protozoa
Consortium (SGPP) in PSI-1 and the New York Center on Membrane Protein Structure (NYCOMPS) in PSI-2. Sesame is also used by a
number of ‘‘R01’’-type laboratories
PINE (1100 jobs submitted; 15% local, 65% non-UW inside USA, 20% outside USA)
NMR approach to larger proteins: SAIL structure
Depositions to PepcDB and lead in developing accompanying data
Lead role in developing protocols and data deﬁnitions with PSI Materials Repository
1945 speciﬁc clones and 8 expression plasmids transferred to the PSI Materials Repository
Training of 37 undergraduate students and 6 high school students in molecular biology and protein chemistry
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123from the NIH Knowledgebase TargetDB (Table 3). At
each stage of the generic pipeline deﬁned by the TargetDB,
CESG’s efforts account for a signiﬁcant fraction of the
total PSI effort on eukaryotes, and CESG contributed 29%
of the structures of human proteins deposited in the PDB.
Laboratory information management
and bioinformatics
Sesame, CESG’s laboratory information management sys-
tem [2], consists of a series of web-based distributed Java
applications designed to organize data generated by pro-
jects in structural genomics, structural biology, and shared
laboratory resources. Sesame allows collaborators on a
given project to enter, process, view, and extract relevant
data, regardless of location, so long as web access is
available. Sesame is a multi-tier system, with data residing
in a relational database. As its associated relational data-
base management system (RDBMS), Sesame supports
Oracle 8.1.7?, Microsoft SQL Server 2005, and Post-
greSQL 8? (and advanced open-source RDBMS). Sesame
is by far the most complete and best-tested, publicly
available LIMS. Full details concerning the Sesame project
can be found at http://www.sesame.wisc.edu. Sesame cur-
rently is being used by a second PSI-2 center (the New
York Consortium on Membrane Protein Structure) and by a
number of other laboratories around the world.
Sesame has undergone steady development to keep up
with evolving technology and the needs of the project.
Modiﬁcations have been made to enable the capture of data
in formats compatible with the requirements of PepcDB
and the Materials Repository. The present system can
handle truncated ORFs, multiple chains, and protein–
ligand complexes. Data entry into Sesame has been
streamlined through the introduction of tablet computers
into the laboratory. Sesame allows users to import into
Sesame both crystallization images and scores from the
CrystalFarm database. A new ‘‘metal assay view’’
organizes metal analyses. Sesame now has the capability of
creating ‘‘genealogy’’ traces that track records back to a
given ORF. A new feature allows URLs to be attached to
Sesame records; these provide links to bioinformatics sites
and to the PDB and BMRB depositions for the target.
Improved data mining tools enable a wide variety of
searches and the creation of specialized reports.
A Sesame application called ‘‘Jar’’, which is accessible
from both the CESG and Sesame websites, manages the
growing number of structure requests from the community
to CESG. Persons requesting structures are asked to enter
information that enables CESG to quickly review the
requests to decide which ones meet the guidelines for
acceptance. Jar supports communications with requestors
to let them know if their target has been accepted and to
inform them about its progress and eventual fate: solved
structure or work stopped as the result of a speciﬁed failure.
Target selection
Targets cloned by CESG in PSI-2 (1044 in total through
March, 2008) included human and other mammalian pro-
teins that have high medical relevance and other proteins
expressed during differentiation of human stem cells.
Human targets (601,58%) representthe majority ofall work
now in progress at CESG. Work in other organisms is
undertaken to test speciﬁc experimental hypothesis on ways
to improve the preparation and structure determination of
eukaryotic proteins. CESG routinely scans TargetDB for
possible conﬂicts with other structural genomics centers and
actively avoids duplication of effort. In the past, CESG used
OMIM (Online Mendelian Inheritance in Man Database) as
the major indicator for biomedical relevance. This approach
was fruitful, in that publications describing structures cho-
sen in this way had a higher impact than those chosen as
fold-space targets.In several cases, it was possible touse the
structure to rationalize the consequences of naturally
occurring human mutations with associated phenotypes.
Table 3 Results from TargetDB, March 6, 2008 (includes PSI-1 and PSI-2)
Selected Work Stopped Cloned Expressed Puriﬁed X-ray NMR In PDB
PSI efforts with all eukaryotic proteins All PSI 59869 14008 36350 18018 3779 267 59 313
% Success 100% 23% 61% 30% 6% \1% \1% 1%
CESG 8201 3106 8006 4254 1110 70 36 102
% Success 100% 38% 98% 52% 14% 1% \1% 1%
CESG as a percentage of PSI effort 14% 22% 22% 24% 29% 26% 61% 33%
PSI efforts with human proteins only All PSI 9310 3496 3922 2318 782 49 18 69
% Success 100% 38% 42% 25% 8% 1% 1% 1%
CESG 2099 620 2075 1300 325 13 7 20
% Success 100% 30% 99% 62% 15% 1% 1% 1%
CESG as a percentage of PSI effort 23% 18% 53% 56% 42% 27% 39% 29%
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123However, use of OMIM as the sole indicator of biomedical
relevance limits the search to the 12,000 human protein
sequences annotated in OMIM and ignores other types of
evidence.
In order to expand the reach of CESG’s biomedical rel-
evance selection criteria, we recently explored the use of a
new metric, which we call the ‘‘HEAT index’’. The HEAT
index measures how ‘‘hot’’ the target is from a medically
relevant standpoint. It equals the sum of: (1) the number of
literature articles associated with the human protein
sequence in NIH’s Protein Information Resource (PIR)
(ref_count); (2) the number of gene ontology annotations
associated with the PIR sequence (GO_count) multiplied by
2; and (3) the number of OMIM annotations associated with
the sequence (OMIM_count) multiplied by 10. Thus:
HEAT index ¼Ref count þ 2   GO count
þ 10   OMIM count
ð1Þ
CESG groups newly selected targets into ‘‘Workgroups’’
(WG), which usually contain 96 targets but may contain
fewer. All of the workgroups launched by CESG in PSI-2
(through March, 2008) are listed in (Table 4). ‘‘Selection
Workgroups’’ are used to investigate project hypotheses,
including best sources for homologs to human medically
relevant proteins. ‘‘Control Workgroups’’ are used to test
new innovations in protein production methods. ‘‘Outside
Request’’ workgroups contain targets nominated by
scientists from outside CESG. Human stem cell
workgroups are collaborative efforts to evaluate novel
targets, often not available in public clone collections, such
as MGC, that are being identiﬁed in differentiating stem
cells by our collaborator Dr. James Thomson.
One of the problems with implementing new technology
is making sure that apparent gains in one step do not have
deleterious effects on subsequent steps. For example,
CESG found that a change made to lower costs of cloning,
which changed the N-terminal cloning artifact on the
puriﬁed protein, led to decreased rates of successful crys-
tallization. To avoid such costly problems in the future,
CESG instituted a panel of test proteins, called the ‘‘Con-
trol Workgroup’’. CESG’s Control Workgroup consists of
24 targets derived from previous CESG efforts. It includes
genes and proteins whose behavior is known at each step,
including PCR ampliﬁcation and cloning, small-scale and
large-scale expression in E. coli cells, expression in cell-
free translation, protein puriﬁcation, proteolysis from
fusion tags, crystallization, and HSQC spectra. Through
use of the Sesame LIMS, all previous trials of these known
targets can be compared with results from trials with
emerging technologies. Some of the proteins in the control
workgroup were chosen because they have an easily rec-
ognized chromophore or an easily assayed enzyme activity,
which facilitates development of function-based screening
protocols. The control workgroup provides a useful plat-
form for validation of the routine operation of various
pipeline procedures and provides a well-understood set of
genes and protein targets for training new researchers.
Study of these genes and proteins provides a baseline for
judging the efﬁcacy of proposed changes at any step of the
research pipeline.
Table 4 Groups of targets (‘‘Workgroups’’) launched by CESG in
PSI-2
Workgroup
designator
(GE.)
Descriptive name of the workgroup
100 Outside Requests WG2: Protein from collaborators;
PSI-1 follow-ups
1455 R&D WG1: Crystallization–; Ligand binding studies
1588 Selection WG1: MGC Vertebrate Clones Sequence-
Structure
1589 Selection WG2: MGC Vertebrate Clones Sequence-
Structure
1590 Selection WG3: MGC Vertebrate Clones Sequence-
Structure
1746 Selection WG4: Galdieria Sequence-Structure
1757 Outside Requests WG3: Raines Onconase mutant;
co-crystalization targets
1789 Outside Requests WG1: cDNA provided by
collaborators
1811 Selection WG5: OMIM Medical Relevance Under
23 kDa
1829 Selection WG6: OMIM Medical Relevance 22–
33 kDa
1855 Selection WG7: C. merolai Sequence-Structure
1866 Human Stem Cell WG1: Thomson/Blommel
1974 Human Stem Cell WG2: Thomson/Junying
1995 Human Stem Cell WG3: Thomson/Bradﬁeld predicted
cDNA
2147 Selection WG8: OMIM Medical Relevance; N-term
signal peptide removal
2182 Outside Requests WG4: Human Rieske protein
2195 Selection WG9: Human sequence-structure less than
27 kD
2196 Selection WG10: Human sequence-structure
27–37 kDa
2350 Outside Requests WG5: PRP24 N1234 ? RNA
co-crystallization
2372 Control WG1: Target Selection Master
2387 Control WG3: Gateway pVP16
2394 Control WG3: pEU-His-Flexi
2398 Control WG2: Flexi Vector pVP68K
2421 Selection WG11: Galdi partners to GE.2422 Human
OMIM targets
2422 Selection WG12: Human OMIM partners to GE.2421
Galdi homologs
2453 Unmodelable domains from yeast
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123In recognition that certain classes of human proteins
may ultimately be unsuitable for structural determination,
CESG postulated that thermophilic eukaryotic genomes
may provide homologs with properties better suited to
structure determination. A pilot project (GE.1746) inves-
tigating a few targets chosen from two eukaryotic
thermophiles (‘‘red algae’’) yielded signiﬁcantly higher
success rates ([10%) for X-ray structure determination
than achieved with human or other vertebrate targets
(*2%). On the basis of these results, CESG designed a
study consisting of 24 human targets of biomedical rele-
vance (GE.2422) and 24 homologues of these targets from
the thermophile Galdieria sulphuraria (GE.2421). All of
these targets are being screened for protein production on
the cell-free and cell-based platforms. Smaller proteins
([24 kDa) are initially examined as NMR targets, and if
they fail in the NMR platform, they are considered for
crystallization trials. Larger proteins are produced with Se-
Met labeling and sent to the X-ray platform. Although this
work accounts for a small portion of the CESG research
effort (139 targets, 13% effort in PSI-2), it has the potential
to yield important new information. If the structure of the
human protein in the pair is solved, this will provide direct
insights. If the structure of only the Galdieria homolog is
solved, it will enable a model to be built of the human
protein. If both structures are solved, their comparison may
indicate reasons for thermostability. Even knowledge about
ways to produce thermostable analogs of human proteins of
biomedical relevance could be of eventual interest.
Target cloning and vector development
Vector design
In PSI-1, CESG perfected separate cloning and vector
production methods for its cell-free and cell-based path-
ways. Although successful, the downside was the added
expense of cloning and sequencing twice. CESG’s expe-
rience with eukaryotic genomes demonstrated that
sequence veriﬁcation of targets is an essential quality
assurance step. CESG has accumulated a great depth of
experience with the complications that arise from work-
ing with eukaryotic genomes, including mismatch with
annotated gene models, differences in splicing, use of
alternative start codons, and other biological complica-
tions. In PSI-2, CESG partnered with Promega in
evaluating the Flexi
Vector cloning approach, which is
less expensive than the Gateway
TM approach adopted in
PSI-1 and which allows a single cloning step to support
both cell-based and cell-free protein expression. Because
sequencing is time consuming, having a single cloning
step that can support high ﬁdelity transfer of a sequence-
veriﬁed gene into many different types of expression
vectors is a useful property of an integrated expression-
testing platform.
The importance of performing tests of new technology
over the complete set of steps comprising a structure
determination pipeline is emphasized by CESG’s work
with the Flexi
Vector and Gateway
TM systems. Project
results showed that Gateway
TM was an efﬁcient cloning
system, but inclusion of the attB recombination site in the
cell-free vector was inhibitory to translation. Substitution
of the Flexi
Vector restriction sites allowed similar
efﬁciency in cloning and transfer of genes to different
expression plasmids. Importantly, the Flexi
Vector
restriction sites were not inhibitory to the cell-free trans-
lation. With this knowledge, CESG ﬁrst tested the least
expensive design for primers with Flexi
Vector, which
also had the consequence of leaving an N-terminal AIA
amino acid sequence on the puriﬁed protein. Testing at the
small-scale expression, large-scale cell growth, and protein
puriﬁcation stages showed that the N-terminal AIA
sequence had no deleterious effect on process efﬁciency.
However, later results indicated that the AIA tag might
interfere with crystallization. Similar studies showed that
inclusion of Roger Tsien’s Flash Tag motif [30] in the
linker region as a possible detection scheme did not
noticeably affect expression or solubility of fusion protein
targets, but had a strong tendency to yield aggregated
protein during aerobic puriﬁcation on Ni-IMAC.
In response to these experimental evaluations obtained
from realistic pipeline operations, CESG designed a new
linker region anddevelopedan integrated cloning procedure
that gives the same target protein from all project vectors
currently being evaluated. This new cloning approach was
fully evaluated by the control workgroup approach descri-
bed above, and as a consequence of the positive results, the
new pVP68K plasmid has been chosen as the new standard
for both cell-free and cell-based protein production plat-
forms. Tests have shown that the PIPE cloning approach
developed by the Joint Center for Structural Genomics [31]
can be used for initial cloning into CESG’s small pEU-Flexi
plasmid used for cell-free protein production, which con-
tains acleavable His-tag. As an efﬁcient alternative, we now
carry out PCR cloning into the small pEU vector, which is
then sequenced. This now enables economical cell-free
screening of each and every new clone for protein produc-
tion and solubility. Following cleavage of the cell-free
target, the sequence is identical to that produced in the
E. coli platform following cleavage of the His-MBP-tag.
Thus the solubility results of proteins produced by the cell-
free and cell-based platforms are directly comparable, and
differences can be related to protein folding problems rather
than intrinsic solubility of the construct.
The modular design of the CESG vectors makes it easy
to switch out various components. The Flexi
Vector
The Center for Eukaryotic Structural Genomics 171
123system allows for rapid and high ﬁdelity transfer of a
cloned and sequence-veriﬁed target gene to any desired
expression context. Vectors that have improved perfor-
mance during auto-induction have been obtained by
manipulation of the promoter for the LacI repressor pro-
tein. Bacterial expression vectors were developed that
allow in vivo cleavage of MBP fusion proteins to liberate a
His8-tagged target protein that can subsequently be pro-
cessed with TEV protease. This vector is hypothesized to
facilitate screening for solubility and automated puriﬁca-
tion. A vector that makes a fusion of the target protein with
the folding chaperone protein trigger factor has been made.
This vector is hypothesized to be of use expressing proteins
that require additional chaperone support for folding. Each
of these vectors is now being tested with targets in control
workgroups (Table 4), and the results from these studies
will be published.
Cell-based protein production
Reﬁnement of the auto-induction approach
The auto-induction approach was developed initially by
William Studier [32] at another PSI center. CESG adopted
this approach and optimized it for the preparation of Se-
Met labeled proteins [9] or stable-isotope labeled proteins
[9]. Since then, CESG has used auto-induction routinely in
its cell-based pipeline. In the course of work spanning
nearly ﬁve years, we encountered unexplained discrepan-
cies between yields at the initial screening and production
stages, problems that had vexed attempts of other PSI
centers to use this method. As a consequence, we launched
a major research effort to understand this system.
The auto-induction method of protein expression in E.
coli is based on diauxic growth resulting from dynamic
function of lac operon regulatory elements (lacO and lacI)
in mixtures of glucose, glycerol, and lactose. Our results
showed that successful execution of auto-induction is
strongly dependent on the plasmid promoter and repressor
construction, on the oxygenation state of the culture, and
on the composition of the auto-induction medium. Thus,
hosts expressing high levels of LacI during aerobic growth
exhibit reduced ability to effectively complete the auto-
induction process. Manipulation of the promoter to give
decreased expression of LacI altered the preference for
lactose consumption in a manner that led to increased
protein expression and partially relieved the sensitivity of
the auto-induction process to the oxygenation state of the
culture. We employed factorial design methods to optimize
the chemically deﬁned growth medium used in the pro-
duction of two model proteins, Photinus luciferase
and enhanced green ﬂuorescent protein, either as unlabeled
or selenomethionine-labeled proteins. The optimizations
included studies of protein production from T7 and T7-lacI
promoter plasmids and from T5 phage promoter plasmids
expressing two levels of LacI. From the analysis of over
500 independent expression results, we identiﬁed combi-
nations of optimized expression media and expression
plasmids that yielded greater than 1000 lg of puriﬁed
protein per ml of expression culture. Figure 2 shows one
plane of a 3D space deﬁned by changes in glucose, glyc-
erol, and lactose concentrations. The media compositions
identiﬁed by these optimizations, which were markedly
different than those published by Studier [32], gave yields
of recombinant GFP as high as 1.5 mg per milliliter of
culture ﬂuid.
Use of the expression vector modiﬁed to attenuate LacI
repressor levels and the optimized auto-induction medium
improved the correlation between the scores from small-
scale screening (aerobic) and large-scale production (oxy-
gen limited) from *50% observed with the prior methods
to *80%. The newly optimized conditions also yield
higher volumetric cell mass. The factorial array of media
conditions includes compositions that yield auto-induction
in early log phase growth, mid-log growth or late-log
growth. These results may explain literature reports that
auto-induction can be either beneﬁcial or deleterious to the
expression of individual proteins. The availability of the
factorial auto-induction medium array allows these anec-
dotal reports to be investigated in a more systematic
manner.
CESG has begun to partner with non-PSI groups to
apply these approaches to their own problems. Some topics
of interest include peptide display methods using cus-
tom-designed MBP-thioredoxin fusion proteins, mam-
malian Rieske proteins, full-length human cytochrome b5
Fig. 2 Topographical map representing protein production results
from a factorially evolved auto-induction medium. Lower production
levels are indicated by blue hues and higher levels by yellow hues.
Experimental design points are shown as black circles
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123reductase, and soluble human cytochrome b5 reductase. In
each case, application of CESG methods has led to robust
high-level expression and, for the proteins containing
cofactors, high-level incorporation. These latter results
continue our experience with lactose-based auto-induction
during expression of metalloproteins dating back to 1994
[33].
Small-scale expression screening and protein production
In 2007, we published a study showing how vector design
and medium evolution could be linked to a rapid 1 ml-scale
puriﬁcation using the Promega Maxwell IMAC-based
puriﬁcation robot [10]. The approach was used to prepare a
Se-Met-labeled protein sample sufﬁcient for an X-ray
structure determination. In addition, the method has been
used to prepare labeled proteins for NMR structural studies
in a one-day growth and puriﬁcation cycle. Each protein
was produced from a 50 ml culture, and the total cost of
each
15N-labeled protein was *$50 ($28 for puriﬁcation
and $22 for media). A single Maxwell robot (*$20 K) is
capable of performing up to 128 puriﬁcations per day,
making this an ideally matched technology for meso-scale
(0.2–2 mg) protein production. This technology also is
appropriate for individual investigators and has been dis-
seminated already to laboratories at UC San Diego and the
Medical College of Wisconsin. As part of this work, we are
continuing to implement a microﬂuidic, automated protein
analysis using a Caliper LabChip 90 to replace SDS-PAGE
methods.
Protein puriﬁcation
The protein puriﬁcation capabilities developed in PSI-1
focused on protocol deﬁnition and developing simple
automation for the A ¨KTA Puriﬁer platform. Over the
period of PSI-2, we have developed the capacity to perform
the routine puriﬁcation of up to 12 protein targets per week,
including extensive data capture at each step of the puri-
ﬁcation process. We use a combination of Ni
2?-IMAC and
preparative gel ﬁltration to prepare all samples from cell-
based expression. With the improved correlation in cell
growth phase described above, we are now beginning to
examine correlations between small-scale predictions and
the ﬁnal protein yield, purity, and other target quality
indicators. These results will be used to further reﬁne our
understanding of the cell-based production pipeline. Drop-
frozen samples of puriﬁed protein are made available for
quality assurance testing (SDS-PAGE, UV–vis, mass
spectra). Upon satisfactory completion of the quality
assurance testing, the protein samples are made available
for transfer to the structure determination groups.
The puriﬁcation team has begun research on the use of
isoelectric focusing as a specialized polishing puriﬁcation
step. For proteins containing cofactors or metal ions that
might be removed by Ni-IMAC chromatography, CESG
has begun to use maltose binding protein afﬁnity as the ﬁrst
puriﬁcation step. This approach has been used successfully
to purify proteins containing iron-sulfur centers, including
soluble Rieske-type ferredoxins from human and mouse
brain. The presence of a soluble Rieske ferredoxin in a
mammal was not known before this work. The structure
showed that the protein is most closely related to the
electron carriers from bacterial multi-component oxygen-
ase systems. The function of the mammalian protein is not
yet known. The puriﬁcation group has also begun studies
on liposome ﬂoating as a specialized puriﬁcation technique
for membrane proteins produced in both E. coli and cell-
free translation. We have shown how this approach can be
used to prepare highly puriﬁed liposomes containing full-
length functional human cytochrome b5.
New efforts on membrane proteins
CESG’s E. coli expression vectors have been shown
to express full-length human cytochrome b5 with the
C-terminal membrane anchor as a soluble fusion protein.
We developed methods to purify the fusion protein in the
absence of detergents and to deliver the full-length func-
tional protein in situ to liposomes upon treatment with TEV
protease. Figure 3a summarizes this useful approach. The
work has been published [34] and is included in a patent
application. Based on this success, CESG will further
investigate the use of this approach for the preparation of
other N- and C-terminal anchored membrane proteins in a
systematic manner.
The liposome preparation method has also been studied
using cell-free translation (Fig. 3b). Proteins currently
selected for study include bacteriorhodopsin (expression
control); stearoyl-CoA desaturases from human, mouse,
and Mycobacterium tuberculosis; sigma-1 receptor
(human, guinea pig, and rat); and laminin-a, b and c from
human stem cells. The Wisconsin Alumni Research
Foundation (WARF) has ﬁled patents on production of
stearoyl-CoA desaturase by this approach.
1 We have found
that cell-free translation in the presence of liposomes gives
1 B. G. Fox, P. Sobrado and Y. Chang. 2006. Cell-free expression
systems for mammalian and mycobacterial desaturases with utility for
drug screening. WARF Case No: P06127US. Wisconsin Alumni
Research Foundation. September 1, 2006; B. G. Fox and Y. Chang.
2006. Novel mycobacterium tuberculosis protein. WARF Case No:
P06129US. Wisconsin Alumni Research Foundation. September 1,
2006; B. G. Fox and Y. Chang. 2007. Inhibition of Mycobacteria
smegmatis C-terminal tail speciﬁc protease (msTsp) and its utility in
enhancement of heterologous expression WARF Case No: 08214US.
Wisconsin Alumni Research Foundation).
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123high level expression and near complete transfer of the
expressed proteins to liposomes. We are collaborating with
Dr. Lloyd Smith (University of Wisconsin Chemistry
Department) to develop efﬁcient protease digest and mass
spectral approaches to map the orientation of expressed
membrane proteins in the liposome bilayer. In the case of
sigma-1 receptor, ligand binding studies undertaken in
collaboration with Dr. A. Ruoho (University of Wisconsin
Pharmacology Department) conﬁrm that a fraction of the
expressed and lipid incorporated protein is capable of
binding ligands, demonstrating a functional state. In the
case of stearoyl-CoA desaturase, the enzyme is a three-
protein complex. We have been able to use cell-free
translation express human stearoyl-CoA desaturase and
simultaneously incorporate exogenously added human cyt
b5 (Fig. 3b). Methods have been developed to introduce
the diiron center into the desaturase, incorporate heme into
cytb5, and the N-terminal anchored cytochrome b5
reductase has been added to the liposome-bound complex
to reconstitute the 3-protein integral membrane complex.
Catalytic assays using [
14C-]-stearoyl-CoA show the in
vitro complex is catalytically active. Moreover, the
expressed protein puriﬁed by the liposome ﬂoating method
is *80% pure by capillary electrophoresis. We are now
working on methods to exchange the liposome for deter-
gents. These efforts are designed to build experience and
analytical procedures suitable for handling a larger set of
membrane proteins proposed by CESG as structural
genomics targets.
Cell-free protein production
Wheat germ cell-free protein production has proven to be
an efﬁcient and economical method for screening targets
for expression and solubility and for making labeled pro-
teins for NMR structural studies. CESG’s cell-free
platform is highly automated. It requires the efforts of only
two FTEs for screening, protein production, and puriﬁca-
tion, as compared to ﬁve FTEs for the cell-based platform.
The overall cell-free process also is much faster at every
step than cell-based.
Previous studies comparing E. coli cell-based and wheat
germ cell-free approaches to preparing labeled proteins for
NMR studies showed that nearly twice as many folded and
soluble proteins resulted from the cell-free approach [17].
Wheatgermcell-freehasbecomearobustplatformatCESG
for the production of labeled proteins for NMR structure
determination [16]. In the past year, CESG has investigated
the production of membrane proteins from wheat germ
extracts in the presence of detergent micelles or liposomes.
Alarge proportion ofthe membraneproteins tried expressed
well and were solubilized under these conditions. These
preliminary results suggest that this may provide a pathway
to producing proteins for structure determination by NMR
spectroscopy or X-ray crystallography.
CESG makes use of a Cell-Free Sciences GenDeco-
der1000
TM robotic system in automating the small-scale
screeningofconstructsforproteinproductionandsolubility.
Thisunitmakesitpossibletocarryoutasmanyas384small-
scale (25-ll) screening reactions per 48-h run. The average
yield is 2–5 lg/well, sufﬁcient for determining expression
levels and solubility by comparing PAGE from total and
soluble protein or for determining function through an
enzymatic activity or ligand binding assay. Current average
supplies costs, including wheat germ extract are: $4/target
for expression-solubility testing and analysis.
Targets that express well in small scale are next screened
at intermediate scale on the Protemist
TM DT-II robotic
system (CellFree Sciences). The Protemist
TM DT-II carries
out fully automated transcription, translation, and batch
method afﬁnity puriﬁcation. Translation is carried out in
bilayer mode, with wheat germ extract and mRNA in the
bottom layer and amino acids and energy source in the top
layer. Six 6-ml samples can be produced in 35 h, including
puriﬁcation, with a yield of 0.1–0.3 mg protein per sample
(0.6–1.8 mgfromallsixsamples).Thecostis*$80/sample
for unlabeled protein or $90/sample for a
15N-labeled
sample. The only additional steps required for producing an
Fig. 3 a Density gradient
capture of cytochrome b5 into
liposomes after in situ
proteolysis of fusion protein
puriﬁed from E. coli or after
wheat germ cell-free translation.
b SDS PAGE analysis of the
density gradient separation of
integral membrane human
stearoyl-CoA desaturase in the
presence of exogenously added
human cytochrome b5
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123NMR sample are buffer exchange and concentration. The
yield is sufﬁcient for buffer screening to determine proper
solution conditions for NMR and for initial screening by
NMR spectroscopy to determine if the protein is folded and
monodisperse.
Large-scale cell-free protein production is carried out on
one of CESG’s two robotic units. The Protemist
TM 10
robotic system is capable of carrying out eight 4-ml
translation reactions per 24 h run; this system requires
preparation of the mRNA off-line. The Protemist
TM 100
robotic system supports eight 4-ml transcription and
translation reactions per 48-h. Typical yields for the Pro-
temist runs are 0.3–0.5 mg puriﬁed protein per ml of
reaction. The cell-free puriﬁcation protocols generally
require less time and effort than the corresponding cell-
based ones, owing to smaller initial volumes and higher
initial purity. Using the latest in GE HIS-TRAP puriﬁcation
technology, IMAC puriﬁcation of His-tagged proteins
requires 40 min of processing time and results in protein
samples that are 75–85% pure. Gel ﬁltration adds an
additional 3 h and can increase the purity to [95% for
proteins \15 kD and to 90% for proteins \20 kD. GST
puriﬁcation results in [95% purity regardless of size;
however, the minimal time to process the sample is greater
than 10 h. These systems are used to make
15N- and
13C,
15N-labeled samples for NMR structure determination
or Se-Met samples for X-ray structure determination. The
average yield is 0.2–0.4 mg of puriﬁed protein/ml of
reaction. Current average supplies costs per 4-ml reaction
(yielding 0.8–1.2 mg protein), including wheat germ
extract, labeled amino acids, and puriﬁcation, is $390 for
[
15N]-protein, $370 for Se-Met–protein and $470 for
[
13C,
15N]-protein.
CESG has been successful in using the Protemist
TM
DT-II cell-free robotic system to translate membrane pro-
teins in the presence of detergent micelles. One of these
proteins has been exchanged into a detergent that is suitable
for NMR studies and has been shown to yield a promising
NMR spectrum (Fig. 4). NMR structural studies on this
target are underway.
NMR data collection and analysis
In collaboration with staff members of the National Mag-
netic Resonance Facility at Madison (NMRFAM), CESG
has developed novel automated approaches to protein
NMR data collection and analysis. An adaptive and inter-
active engine for identifying peaks in 3D triple-resonance
spectra in a probabilistic manner is based on ideas of
reduced-dimensionality and tilted-plane data collection.
The method, called ‘‘High-Resolution Iterative Frequency
Identiﬁcation’’ (HIFI)-NMR [21], eliminates the spectral
reconstruction step and concentrates on ﬁnding the best
model for the peak positions. Optimal 2D spectra are
chosen on the ﬂy. In so doing, the algorithm can in 2 h
create automatically a statistically annotated peak list that
would take over 20 h to produce by conventional means.
The HIFI software is tasked with the job of identifying the
chemical shifts of all the peaks that would appear in a 3D
spectrum. After each new 2D spectrum is acquired at a
different angle, the software reviews all data and updates
its model. It also judges when all possible peaks have been
captured. The current HIFI-NMR software can collect data
from the set of NMR experiments needed to determine the
solution structure of a small protein and turn these into
peak lists for the next step in the analysis. The peak lists
generated by HIFI-NMR along with the sequence of the
protein are input to a software package called PISTACHIO
(Probabilistic Identiﬁcation of Spin sysTems and their
Assignments including Coil-Helix Inference as Output)
[23]. The output of PISTACHIO is chemical-shift assign-
ments represented as a series of minimum energy
conﬁgurations ranked according to their probable correct-
ness, with multiple attributions in ambiguous cases. With
typical data sets, initial PISTACHIO runs yield reliable
backbone assignments for more than 90% of the amino
acid residues and reliable side chain assignments with
greater than 75% completeness. The assigned data are then
run through the LACS [24] (Linear Analysis of Chemical
Shifts) software, which corrects possible referencing
problems and identiﬁes assignment outliers. The software
package PECAN [27] (Protein Energetic Conformational
ANalysis) then carries out probabilistic secondary structure
determination.
Fig. 4
1H–
15N TROSY HSQC spectrum (600 MHz) of a
15N-labeled
membrane protein produced in the wheat germ cell-free system
containing detergent (Brij35) and subsequently exchanged into 0.5%
Fos-choline-12 (lipid-like zwitterionic detergent). The protein con-
tains four Trp residues, whose signals are clearly resolved in the lower
left corner of the spectrum. The sample temperature was 25C. The
spectrum is the average of 256 transients
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and PECAN) have now been fully integrated into a pipe-
line, called PINE-NMR. PINE handles input data from a
wide variety of NMR experiments, including HCCH
TOCSY (important for side chain assignments). PINE is
freely available from a web server (http://miranda.nmrfam.
wisc.edu/PINE/). PINE has been used by NMR spectros-
copists worldwide for over 1,000 assignment runs. Current
efforts are focused on linking HIFI-NMR and PINE so that
full data analysis follows directly from fast data collection.
A HIFI-NMR approach to the collection of reduced
dipolar coupling (RDC) data from a partially oriented
protein, called HIFI-C [22], can accelerate the collection of
these data by a factor of 3–5. The increase in speed is
important, because many proteins are unstable in oriented
media needed for their partial orientation and begin to
precipitate over time. Another advantage of this approach
is that the splittings are determined multiple times (from
data at different tilted angles) so that error bars can be
associated with the RDC values.
Technology development for X-ray crystallography
Crystallization screening
The database and automation-centric approach of CESG to
identiﬁcation of crystal leads and optimization of diffrac-
tion quality crystals has continued to mature. In PSI-1, and
continuing through the second year of PSI-2, CESG
assembled all components of a high-throughput pipeline,
and optimized them individually and as an integrated
platform. Recently, a Mosquito plate setup robot has been
added, which lowers the required crystallization volumes
from 1 ll to 100 nl. The Mosquito produces droplets that
are well suited for automatic image classiﬁcation, reduces
the sample requirements for screening by a factor of 10,
allows us to screen in depth with less sample, and expands
the range of screened conditions, to include additive
screens.
Collaborative work between the Sesame development
team and the crystallography group continues to build on
the robust platform already in place. Most notably, a
transport mechanism has been developed for moving scores
and images from the CrystalFarm databases to Sesame.
This constitutes a critical step toward CESG’s goal of
uploading all crystallomics data and images to PepcDB.
Signiﬁcant research effort was expended toward ana-
lyzing data from our 48-condition additive screen and
expanding it to 96 conditions. The current formulation of
our additive screen can be described as a ‘‘compacted’’
version of our original cofactor heavy additive screen into a
few cocktails, and incorporation of additional reagents
known to facilitate protein crystallization. The current
additive screen also includes a number of complex mix-
tures of natural products. Additionally, reagents intended to
modify protein side-chains have been included. Wide-scale
implementation of the new additive screen is possible
primarily because of the acquisition of the Mosquito robot.
Support for capturing the data from additive screening was
completed in year 1 of PSI-2.
Once monodisperse proteins are produced, the bottle-
neck for solving crystal structures is the crystallization
process. This is generally viewed as a combinatorial or
incomplete factorial design process, with thousands of
experiments required to obtain suitable crystals for a
structure determination. Robotics have been integrated into
many steps of the process, including the management of
solutions for crystallization, setting up of trays for crystal
screening, plate handling for time series image capture,
crystal lead identiﬁcation, and optimization of crystal
conditions. This latter step often beneﬁts from the expe-
rience of crystallographers, and there is no standard
algorithm. To aid in the process of converting conceptual
principles to practical experiments in protein crystal opti-
mization, we have developed a tool called Crystal Farm
Pro, a Java application which queries the database of the
Crystal Farm imaging system, presents screening data to
the crystallographer, and generates solution conditions for
optimization experiments based on the contents of original
screening conditions. The design of the software also
includes hooks to implement liquid handler control scripts
to robotically generate the solutions for optimization plates
from stock solutions. Progress in the last year includes its
deployment at several third party sites, better network
connectivity, new data mining and statistical analyses of
crystallization outcomes, and various improvements in
error handling.
CESG’s crystallization imaging needs continue to be
well served by a pair of 400-position CrystalFarm imaging
robots. Our collaborative agreement with Bruker has let to
important advances in our CrystalPro tool. Signiﬁcantly, a
built-in statistical test now provides pair-wise comparisons
of crystallization outcomes, as will be needed to facilitate
analysis of data from the control workgroup, which has
progressed to crystallization screening. Another new fea-
ture supports deep data-mining of crystallization outcomes,
across all instances of a given screen over the entire
CrystalFarm database. The presentation of data on crys-
tallization outcomes has been improved by the provision of
detailed statistical reports on constituents associated with
positive crystallization outcomes for a given target. These
reports, which facilitate the optimization of leads, will be
especially useful in analyzing data from our new additive
screen.
During year 1 of PSI-2, our project provided a database
of scored images to Bruker and Discovery Partners to
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123facilitate the automatic classiﬁcation of crystallization
images. The challenge of automatic crystallization image
classiﬁcation has now been taken up by a collaboration
between Phillips, Amos Ron (Computer Science, UW-
Madison) and Robert Nowak (ECE UW-Madison.) A
previously developed baseline algorithm has been adapted
to function with images produced with current best practice
(100–200 nanoliter droplets set with the Mosquito robot
and acquired with the CrystalFarm imaging system).
Efforts to improve the robustness of the methodology and
sharpen the classiﬁcation are ongoing.
In-house production of reagents
As an important part of efforts to control costs, CESG has
used its own protein production platform to produce pro-
tein reagents for project use. The reﬁned auto-induction
and vector design approaches were ﬁrst applied to tobacco
etch virus NIa proteinase (TEV protease) production. TEV
protease is an important tool for the removal of fusion tags
from recombinant proteins. From this work, CESG cor-
rected numerous incorrect statements in the literature about
the relative stability of various TEV protease constructs,
and obtained expression of TEV protease at high levels and
with high solubility by using auto-induction medium at
37C. In combination with the expression work, an auto-
mated two-step puriﬁcation protocol was developed that
yielded His-tagged TEV protease with[99% purity, high
catalytic activity, and puriﬁed yields of *400 mg/l of
expression culture (*15 mg pure TEV protease per g of E.
coli cell paste). Methods for producing glutathione S-
transferase tagged TEV with similar yields (*12 mg of
pure protease fusion per g of E. coli cell paste) were also
published. Since publication of this work [11], numerous
laboratories from all over the world have requested these
vectors, including several NIH PSI centers. These same
approaches have also been used to obtain puriﬁed, highly
active human rhinovirus 3C protease, and the ﬁrst requests
for this plasmid have begun to arrive.
The Flexi
Vector cloning system requires the use of a
high concentration of T4 DNA ligase. Thus, T4 DNA
ligase has become a major cost. As an approach to low-
ering this cost, we tested the possibility of making the
ligase in house, as we do with TEV protease. An E. coli
expression plasmid was obtained for a His6 tagged T4
DNA ligase using a new project vector. Preliminary
experiments showed that it expressed well in our auto-
induction medium and yielded a protein of high purity after
only one IMAC puriﬁcation step. The isolated protein is as
active as the commercially available high concentration
ligase in the standard assay used by Promega. If the
in-house prepared ligase proves to works well in our
Flexi
Vector cloning protocol, we will adopt this approach
to lowering costs.
Discussion
CESG is a leader in bringing structural genomics approa-
ches to bear on human and other eukaryotic proteins. The
understanding gained will assist in successfully leveraging
PSI-derived structural genomics methods into more com-
plicated, but highly relevant, biological topics such as
alternative splicing patterns, temporal patterns of gene
expression in stem cell differentiation, tumor cell biogen-
esis, and many other biological phenomena that are unique
to eukaryotes.
CESG worked with the PSI Materials Repository (PSI-
MR) and the University of Wisconsin to develop
acceptable material transfer agreements for this important
aspect of sharing the results of the PSI. CESG and the
PSI-MR also developed required protocols deﬁning the
format of the electronic documents to be transferred
between the depositor and the PSI-MR prior to shipment
of plasmids, establishing the string of check-offs that
must occur before plasmids are shipped, and developing
deﬁnitions and descriptors for experimental results asso-
ciated with each plasmid deposition. All depositors to the
PSI-MR will use these check-offs. As a result of these
efforts, CESG was the ﬁrst PSI center to transfer mate-
rials to PSI-MR.
The Sesame LIMS system was modiﬁed to include
actions to track PSI-MR sample selection, all phases of
preparation, and availability of the target to the general
public though the PSI-MR. After the electronic processes
were deemed acceptable, CESG deposited 96 target clones
into the PSI-MR as a pilot study for the physical transfer
process. This pilot project was successfully concluded
when we were able to re-order some of our plasmids from
the PSI-MR and receive them back at CESG. CESG has
currently transferred 1945 targets to the PSI-MR, and we
anticipate clearing our backlog of clones by May, 2009.
Further reﬁnements in information exchange between PSI-
MR and CESG are ongoing.
CESG is the now the ﬁrst PSI center to provide target-
speciﬁc experimental results such as g of cell paste used in
the puriﬁcation, mg yield of protein, and other experi-
mental observables captured in the Sesame LIMS system.
At this time, no other PSI center is providing this level of
detail, which will be essential for the biological community
to make broader use of the NIH Knowledge Base. CESG
has twenty-two technology dissemination reports available
through PSI-KB at http://cci.lbl.gov/kb-tech/. All CESG
peer reviewed publications (total of 130) have been regis-
tered with the PSI-KB.
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